The DQ Barrier: Improving Organ Allocation Equity Using HLA-DQ Information

Anat R. Tambur,[1,4] Joseph R. Leventhal,[2] Jennifer R. Zitzner,[1] R. Carlin Walsh,[1] and John J. Friedewald[3]

Background. The United Network for Organ Sharing algorithm for deceased-donor kidney allocation considers only the human leukocyte antigen (HLA)-A, HLA-B, and HLA-DR loci. Although HLA-DQ serologic specificities can be entered as unacceptable antigens, they are assigned only by the identity of the DQβ chain, disregarding the role of the similarly polymorphic α chain. DQα/β combinations result in unique antigenic epitopes, which serve as targets to different antibodies. Therefore, the presence of HLA antibodies to one DQα/β combination should not preclude negative crossmatch (XM) against another combination. In this retrospective analysis, patients were allowed XM against a particular donor if they had antibodies to some, but not all, DQα/β allele combinations with the donor serologic HLA-DQ antigens.

Methods. HLA antibody signature was obtained using solid-phase Luminex-based antibody analysis. Results were captured at the high-resolution level (as provided by the positive beads). Potential donors were typed to include information on both HLA-DQA and HLA-DQB alleles.

Results. Of the 1130 flow XM assays performed, 147 patients had antibodies to donor serologic HLA-DQ antigens. Thirty-five of those patients had antibodies to an allelic DQα/β combination within the donor serologic DQ specificity that were different from the donor's DQα/β, leading to negative flow XM results (24%). Virtual XM, accounting for donor DQα/β combinations, successfully predicts more than 98% of XM outcomes.

Conclusions. In patients with allelic DQα/β antibodies, denying the opportunity for XM based on serologically defined unacceptable antigens can disadvantage the patient. Larger cohort studies are required to substantiate our observation. Introducing DQα/β combination information may increase virtual XM accuracy and organ allocation equity.

Keywords: HLA-DQα, HLA-DQβ, Organ equity, Epitope.

(*Transplantation* 2013;95: 00–00)

Human leukocyte antigen (HLA) class II antibodies have not been considered a contraindication to transplantation for many years. Even with the increased understanding of the significance of a positive B-cell crossmatch (XM), the main targets of interest were antibodies to HLA-DR. The significance of other HLA class II antibodies (HLA-DQ and HLA-DP) has only recently come to light (*1–4*). Initial reports have documented the incidence of donor-specific HLA-DQ antibodies (*5–7*). More recently, several groups have reported that HLA-DQ antibodies were the most common donor-specific antibodies (DSA) developed de novo after transplantation and concluded that these antibodies likely contribute to inferior graft outcome (*8–10*). Importantly, Walsh and colleagues (*11*) found that the most frequent antibodies associated with late antibody-mediated rejection were HLA-DQ DSA.

The United Network for Organ Sharing (UNOS) algorithm for deceased-donor kidney allocation still prioritizes candidates with a zero antigen mismatched donor, considering only the HLA-A, HLA-B, and HLA-DR loci for this purpose (*12*). Although HLA-DQ serologic specificities can be entered as unacceptable antigens, these specificities are assigned only by the identity of the DQβ chain, completely disregarding the role of the other half of the HLA-DQ molecule—the α chain (see **Figure S1, SDC**, http://links.lww.com/TP/A753).

The authors declare no funding or conflicts of interest.

[1] Transplant Immunology Laboratory, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.

[2] Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.

[3] Department of Internal Medicine, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.

[4] Address correspondence to: Anat R. Tambur, D.M.D., Ph.D., D[ABHI], Transplant Immunology Laboratory, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue, Tarry Building Suite 11-711, Chicago, IL 60611-3008.
E-mail: a-tambur@northwestern.edu

A.R.T. participated in the research design, performance of the research, data analysis, and writing of the article. J.R.L., R.C.W., and J.J.F. participated in the writing of the article. J.R.Z. participated in the performance of the research and writing of the article.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.transplantjournal.com).

Received 21 August 2012. Revision requested 31 August 2012.
Accepted 4 October 2012.

ISSN: 0041-1337/13/9504-00
DOI: 10.1097/TP.0b013e318277b30b

Moreover, allele-level differences between some of the DQβ specificities (for example, alleles of HLA-DQ5 such as *DQB1*05:01* and *DQB1*05:02*) are ignored using the current approach.

Whereas some centers have considered antibodies directed specifically at the DQα chain (*13, 14*), our group has shown previously that HLA-DQ molecules are recognized by antibodies as unique combinations of DQα and DQβ chains (*15, 16*). These two chains are encoded by distinct genes at the molecular level but are expressed as a unique, single protein on the cell surface where they are accessible to antibodies or T-cell receptors (TCR). HLA-DR molecules are also formed by combinations of DRα and DRβ chains; however, because the DRα molecule is not polymorphic, it does not contribute to allelic variation between the different DR antigens. Thus, the current practice of typing only for the DRβ chain is sufficient.

In this retrospective study, we tested the impact of assigning HLA-DQ antibodies using the conventional UNOS system (serologic equivalents) versus using the complete HLA-DQ information (molecular definition of the combined DQα and DQβ chains) as it affects patients' access to transplantation. In our region, Gift of Hope (GOH) organ procurement organization laboratory has a mandate to perform XM assays for all deceased-donor kidney offers. The individual transplant centers enter into UNet the HLA specificities that are considered unacceptable. Patients are awarded calculated panel reactive antibody (cPRA) points based on these assignments but are prohibited from being crossmatched with donors expressing these HLA antigens. The Northwestern Comprehensive Transplant Center is willing to consider accepting potential donors with low to moderate immunologic risk depending on patient specific criteria; therefore, only strong HLA antibodies are considered unacceptable. Given our experience with HLA-DQ antibodies, our center has chosen not to report strong HLA-DQ antibodies as unacceptable unless the complete serologic specificity (all DQα/β allele combinations within this antigen assignment) is positive. For example, if some, but not all, HLA-DQ8 alleles are strongly positive, HLA-DQ8 will not be reported as an unacceptable antigen. Our center maintains an internal database with all antibody specificities and their strength to perform real-time virtual XM when a donor opportunity arises. This database is shared with the GOH HLA laboratory on a monthly basis. This arrangement provided us with the unique opportunity to test the impact of entering unacceptable HLA-DQ specificities using the serologic assignment, as it is currently performed in UNet, versus our approach that assigns specificities based on the complete HLA-DQα/β combinations, and assess its potential impact on accessibility to organ transplantation.

RESULTS

Patient Population

Between 1 January 2011 and 31 December 2011, the Northwestern Comprehensive Transplant Center HLA laboratory performed 2037 assays using solid-phase HLA flow PRA tests. Of these, 1173 (58%) patients were sensitized and continued analysis using the single antigen bead (SAB) assay. As shown in Figure 1, 9% of sensitized patients had antibodies against HLA class II antigens alone and additional 48% had antibodies against both class I and II specificities. Antibody signature analysis revealed that 56% of these patients had antibodies directed at HLA-DQ targets; of those, 31% had antibodies against HLA-DQ only, 25% had antibodies directed at both HLA-DR and HLA-DQ, and 44% had antibodies against HLA-DR, HLA-DQ, and HLA-DP. The lower portion of Figure 1 presents a graphic distribution of HLA-DQ antibodies by the relative strength as determined in our center. As can be seen, the vast majority of patients who possessed DQ antibodies had at least one specificity that was assigned as strong (46%; unacceptable) or moderate (39%; relative high risk).

Crossmatch Assays

During calendar year 2011, GOH HLA laboratory performed 1130 XM assays for Northwestern Comprehensive Transplant Center (Table 1). Assays were performed against a total of 259 potential donors. In retrospective analysis, it was found that, of the positive XM assays, 112 were positive due at least in part to donor-specific HLA-DQ antibodies (10% of all assays). In 64 of 112 (57%) assays, in addition to a moderate to strong donor-specific HLA-DQ antibodies, other HLA DSA may have contributed to the positive B-cell flow XM. These patients were not excluded from the match-run because they had only some antibodies to the donor-specific serologic HLA-DQ specificity, but not to all DQα/β allele combinations within this antigen assignment, and therefore, per our algorithm, were not considered unacceptable. In three of the cases (two patients), the donor reactivity might have been explained by a pattern of antibody responses currently considered as a "DQA antibody". In 35 additional cases, however, although the patients had moderate to strong antibodies against the donor-specific DQ serologic specificity, no antibodies were detected against the specific donor HLA-DQα/β combination; in other words, no antibodies to the donor-specific HLA-DQ allele were present. These 35 XM assays were negative and would have enabled these patients to receive an organ from that donor. Thus, using serologic HLA-DQ assignment, a total of 147 patients (112+35) would have been screened out of the XM tray against a specific donor. Using our allele-level approach, 35/147=24% were able to proceed and obtain a negative XM. It is important to state that using the complete donor DQ typing (α/β) and the complete antibody signature, the accuracy of prediction of the virtual XM in these 147 cases was more than 98%. Table 2 provides demographic information specific to this group of patients. All but one patient had at least one previous transplant in their history, with 41% having more than one prior transplant. Their sensitization level was quite high as indicated by the peak and current PRA values for HLA class I and II (65% and 91% for peak PRA and 48% and 69% for current PRA, respectively).

A Representative Case

A 67-year-old Hispanic male received a kidney transplant in 2003 from his haplotype-matched sibling. The transplantation failed, and in 2009, the patient underwent a transplant nephrectomy. The patient was placed on the deceased-donor waiting list with class I and II PRA values of 87% and 90%, respectively. The pertinent details regarding a potential kidney offer in 2011 are presented in Table 3.



FIGURE 1. HLA antibody signature of patients awaiting kidney transplantation at the Northwestern Comprehensive Transplant Center. Between 1 January 2011 and 31 December 2011, 2037 patients were tested for the presence of HLA antibodies in our laboratory. Fifty-eight percent of patients were sensitized with the relative distribution as presented in the pie chart on the top right-hand side. Of the patients that exhibit class II specificities, 56% had antibodies to HLA-DQ. The antibody make-up and strength of antibodies are presented in the lower portion as bar charts. HLA, human leukocyte antigen.

Solid-phase single antigen Luminex analysis revealed that, in addition to many other antibody specificities, three of the five beads carrying the serologic DQ2 specificities and two of the five beads carrying the serologic DQ7 specificities were strongly positive (mean fluorescence intensity [MFI] values of >10,000). Following our center's philosophy—that only specificities in which all DQ alleles are positive are listed as unacceptable antigens—DQ2 and DQ7 were not listed as unacceptable antigens for this patient, leading to his eligibility for XM with the specific donor (donor HLA typing is provided in Table 3). After evaluating the complete donor DQα/β combinations (typed by the GOH HLA laboratory as *DQA1*05:01/DQB1*02:01* and *DQA1*05:01/DQB1*03:01*), it was clear that the patient had no antibodies to the donor-specific HLA-DQα/β combination and thus had no DSA. Predictably, the T-cell and B-cell XM results were negative. The three-dimensional structure of the HLA-DQ molecule, indicating the specific area in which the positive DQ2 and DQ7 allelic antibodies differ from the negative DQ2 and DQ7 allelic antibodies, is presented in Figure 2. This area/epitope is accessible to antibody binding as well as for TCR recognition. Without the ability to take into consideration the HLA-DQα/β information, this highly sensitized patient would have been denied the offer from this donor and would have missed an opportunity to find a compatible kidney. Our approach increased accessibility to transplant for this patient and for 24% of patients with serologic, but not allelic, DQ DSA.

DISCUSSION

One of the major contributions to the field of histocompatibility in recent years was the introduction of the solid-phase single antigen Luminex assay (*17, 18*). Other than the increased sensitivity that the assay provides, the ability to test for individual HLA targets allowed us to overcome limitations in determining the exact locus contributing to the positive response. This is due in part to the strong linkage disequilibrium between the different HLA loci and is even more noticeable when trying to distinguish between antibodies against HLA class II molecules—separating antibodies against HLA-DQ or HLA-DP from antibodies targeting HLA-DR. Between the two vendors of Luminex-based SAB assays, there are currently 43 different alleles of HLA-DQ specificities. Those represent a total of seven serologic DQ antigens (HLA-DQ2, HLA-DQ4, HLA-DQ5, HLA-DQ6, HLA-DQ7, HLA-DQ8, and HLA-DQ9), providing multiple alleles for each serologic specificity. A list of these combinations is provided in Table S1 (see **SDC,** http://links.lww.com/TP/A753). Therefore, the information obtained by the SAB assay is significantly more informative than the one entered into the UNet unacceptable antigen database. Moreover, most

TABLE 1. XM assays performed by GOH for Northwestern Comprehensive Transplant Center between 1 January 2011 and 31 December 2011

Total XM assays performed	1130
Total potential donors	259
Number of positive XM assays due to HLA-DQ DSA[a]	112
Number of negative XM assays with serologic HLA-DQ DSA	35

[a] All positive B-cell flow XM assays that could have been due to HLA-DQ DSA were considered as such, even if additional loci DSA were present.